News

The collaboration brings together LEO Pharma’s “expertise” in medical dermatology and DEBRA Research’s pharmaceutical experience to develop novel medicines for this condition. DEBRA Research managing director Prof Hubert Truebel

Concurrently, the company also secured a funding of $27m in Series B round. The proceeds are set to be utilised for progressing the therapy through a Phase I

The acquisition primarily comprises cash payments, with a smaller portion in the form of BioNTech American Depositary Shares. In addition, there are potential performance-based payments of up to

The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year,

This places the company’s valuation at $525m. Transformation Capital led the funding round, with participation from current investors like World Innovation Lab, OCV Partners, UP2398, Khosla Ventures, Cone

Additionally, the company is on track to submit a marketing authorisation application (MAA) to the European Medicines Agency (EMA) in the first quarter of this year. The Division

Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation,

Utilising its collaboration with Microsoft and a team of multidisciplinary scientists, the company is poised to disrupt the conventional therapeutic discovery model. The company was co-founded by Dr

The application is currently being evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Mavorixafor would become the first drug for this syndrome in the European